Notice of Application to Register a Trade Name Product (Notice No. MPI ACVM 14)
Notice is given under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”), of the following application to register a trade name product under section 9(1) of the Act:
Trade Name: Purevax 3
Reference: A012115
Active Ingredients and Concentrations:
Each 1ml (0.5mL) dose contains:
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ≥ 104.9 CCID50
Inactivated feline calicivirus (FCV 421 and FCV G1 strains) ≥ 2.0 ELISA U.
Attenuated feline panleukopenia virus (PLI IV) ≥ 103.5 CCID50
Formulation Type: Lyophilisate with aqueous diluent
Application Method/Administration Route: Subcutaneous
Use Claim:
For active immunization of cats aged 8 weeks and older:
Any person may make a written submission to the director-general concerning this application.
Under sections 16 and 17 of the Act, a written submission:
Each submission must state the trade name product(s) to which it relates. Under section 18 of the Act, a copy of every submission will be forwarded to the applicant.
The following address is:
ACVM Team, Ministry for Primary Industries, Charles Fergusson Building, 38–42 Bowen Street, Pipitea, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140. Email: acvm.consultation@mpi.govt.nz.
MPI encourages submission by email.
The applicant’s address for service is:
Boehringer Ingelheim Animal Health New Zealand Limited, Level 2, 3 Te Kehu Way, Mount Wellington, Auckland 1060. Postal Address: PO Box 76 211, Manukau, Auckland 2241.
Dated at Wellington this 18th day of July 2024.
SHALEEN NARAYAN, Manager Approvals, Ministry for Primary Industries (acting under delegated authority).